Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Cell

Volumn 167, Issue 6, 2016, Pages 1540-1554.e12

  Benci, Joseph L ^a   Xu, Bihui ^a   Qiu, Yu ^a   Wu, Tony J ^a   Dada, Hannah ^a   Twyman Saint Victor, Christina ^a   Cucolo, Lisa ^a   Lee, David S M ^a   Pauken, Kristen E ^b   Huang, Alexander C ^a,b   Gangadhar, Tara C ^a   Amaravadi, Ravi K ^a   Schuchter, Lynn M ^a   Feldman, Michael D ^b   Ishwaran, Hemant ^c   Vonderheide, Robert H ^a,b   Maity, Amit ^a   Wherry, E John ^b   Minn, Andy J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; RUXOLITINIB; STAT1 PROTEIN; CD274 PROTEIN, MOUSE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER TISSUE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; LYMPHOCYTE SUBPOPULATION; METASTATIC MELANOMA; MONOTHERAPY; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DRUG RESISTANCE; IMMUNOLOGY; MELANOMA; METABOLISM; RADIOIMMUNOTHERAPY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIGENS, CD274; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; INTERFERONS; MELANOMA; MICE; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 85001996779     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.11.022     Document Type: Article

References (40)

1. Blackburn, S.D., Shin, H., Freeman, G.J., Wherry, E.J., Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl. Acad. Sci. USA 105 (2008), 15016–15021.
2. Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., Betts, M.R., Freeman, G.J., Vignali, D.A.A., Wherry, E.J., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10 (2009), 29–37.
3. Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y., Greenleaf, W.J., Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10 (2013), 1213–1218.
4. Chen, X., Ishwaran, H., Random forests for genomic data analysis. Genomics 99 (2012), 323–329.
5. Cheon, H., Stark, G.R., Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. USA 106 (2009), 9373–9378.
6. Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., Lee, H., Arthur, C.D., White, J.M., Kalinke, U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
7. Dighe, A.S., Richards, E., Old, L.J., Schreiber, R.D., Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1 (1994), 447–456.
8. Fu, J., Kanne, D.B., Leong, M., Glickman, L.H., McWhirter, S.M., Lemmens, E., Mechette, K., Leong, J.J., Lauer, P., Liu, W., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med., 7, 2015, 283ra52.
9. Gajewski, T.F., Fuertes, M., Spaapen, R., Zheng, Y., Kline, J., Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 23 (2011), 286–292.
10. Galon, J., Angell, H.K., Bedognetti, D., Marincola, F.M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26.
11. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167 (2016), 397–404.e9.
12. He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. Follicular CXCR5-expressing CD8(+) T cells curtail chronic viral infection. Nature 537 (2016), 412–428.
13. Herbst, R.S., Soria, J.-C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
14. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165 (2016), 35–44.
15. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8(+) T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
16. Ishwaran, H., Kogalur, U.B., Gorodeski, E.Z., Minn, A.J., Lauer, M.S., High-Dimensional Variable Selection for Survival Data. J. Am. Stat. Assoc. 105 (2010), 205–217.
17. Johnson, D.B., Balko, J.M., Compton, M.L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M.R., Bloomer, T.L., et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N. Engl. J. Med. 375 (2016), 1749–1755.
18. McWilliams, J.A., McGurran, S.M., Dow, S.W., Slansky, J.E., Kedl, R.M., A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J. Immunol. 177 (2006), 155–161.
19. Minn, A.J., Wherry, E.J., Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. Cell 165 (2016), 272–275.
20. Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27 (2014), 16–25.
21. Ng, C.T., Sullivan, B.M., Teijaro, J.R., Lee, A.M., Welch, M., Rice, S., Sheehan, K.C.F., Schreiber, R.D., Oldstone, M.B.A., Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 17 (2015), 653–661.
22. Paley, M.A., Kroy, D.C., Odorizzi, P.M., Johnnidis, J.B., Dolfi, D.V., Barnett, B.E., Bikoff, E.K., Robertson, E.J., Lauer, G.M., Reiner, S.L., Wherry, E.J., Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338 (2012), 1220–1225.
23. Pauken, K.E., Wherry, E.J., Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36 (2015), 265–276.
24. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science, 2016, aaf2807.
25. Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H.A., Petrylak, D.P., Teng, S.-L., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
26. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
27. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
28. Sandler, N.G., Bosinger, S.E., Estes, J.D., Zhu, R.T.R., Tharp, G.K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K.N., del Prete, G.Q., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511 (2014), 601–605.
29. Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., Gajewski, T.F., Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci. Transl. Med., 5, 2013, 200ra116.
30. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med., 4, 2012, 127ra37.
31. Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20 (2014), 5064–5074.
32. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
33. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
34. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
35. Utzschneider, D.T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D.P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity 45 (2016), 415–427.
36. Vanpouille-Box, C., Diamond, J.M., Pilones, K.A., Zavadil, J., Babb, J.S., Formenti, S.C., Barcellos-Hoff, M.H., Demaria, S., TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 75 (2015), 2232–2242.
37. Weichselbaum, R.R., Ishwaran, H., Yoon, T., Nuyten, D.S.A., Baker, S.W., Khodarev, N., Su, A.W., Shaikh, A.Y., Roach, P., Kreike, B., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 105 (2008), 18490–18495.
38. Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15 (2015), 486–499.
39. Wilson, E.B., Yamada, D.H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B.J., Karp, C.L., Brooks, D.G., Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340 (2013), 202–207.
40. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N. Engl. J. Med. 375 (2016), 819–829.